Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr. Reddy's Laboratories Ltd. Vice-Chairman and CEO, G V Prasad today signed a Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

28 Jul 2011

BioSante to offer and sell shares of common stock in an underwritten public offering

BioSante Pharmaceuticals, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by BioSante.

28 Jul 2011

Dense breasts raise risk of breast cancer

A new study supported by the National Cancer Institute found a higher cancer risk for women with dense breasts. It's the tissue in women's breast that can differ by heredity, from more fatty to more dense tissue. Fatty tissue shows up dark on a mammogram, but fibrous or dense tissue shows up white. So do small tumors, which can make them hard to find. The study was published in the July 27 online edition of the Journal of the National Cancer Institute.

27 Jul 2011

Breast cancer survival and lymph nodes

A large new study has found that a lymph node-sparing test hailed as revolutionary for its conservative approach does not lead to longer survival times for women undergoing lumpectomies whose early-stage breast cancer has spread microscopically.

27 Jul 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

CytRx prices underwritten public offering of common stock

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of approximately $20.4 million.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

MR-guided focused ultrasound prior to radiation therapy could treat cancer

Hypoxic tumor cells usually resist radiation and chemotherapy, making them a key challenge in treating cancer. Researcher Xin Chen, Ph.D. believes that MR-guided focused ultrasound could reduce this problem, benefiting patients with malignant solid tumors in areas such as the liver, prostate and breast.

27 Jul 2011

Women with early-stage breast cancer do not benefit from lymph node removal

A new study shows that removing lymph nodes due to the presence of occult, or microscopic, cancer cells found in the sentinel lymph node - the one closest to the tumor -- has no impact on survival outcomes of women with early-stage breast cancer.

27 Jul 2011

Lipofilling found safe after breast cancer surgery

Preliminary experience suggests that lipofilling—using fat from elsewhere in the patient's body for contouring of the breasts—is a safe procedure for women who have undergone breast cancer surgery, reports a study in the August issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

27 Jul 2011

High-dose vitamin D reduces musculoskeletal pain in breast cancer patients

High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.

27 Jul 2011

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris Inc. today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

27 Jul 2011

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company's lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.

27 Jul 2011

Ceridia completes CER006 Phase 1 Proof-of-Concept study in humans

Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Lack of genetic screening for cancers

In a new study published Monday in the journal Cancer, it was noted that while genetic testing to check if a woman has the BRCA1 or BRCA2 mutations can be a useful tool for preventing breast cancer and ovarian cancer in some cases, many doctors are not referring patients.

26 Jul 2011

Racal differences in breast cancer survival: Study

Black women are more likely to die from breast cancer than white women with obesity considered a significant factor. But a new study shows that that the cause of the difference does not lie in obesity alone. As a group, black women in the U.S. tend to be heavier than whites and researchers had thought that might explain why only 78 percent survive five years after diagnosis, compared to 90 percent of white women.

26 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Kadmon, Dyax enter license agreement for antibody phage display libraries

Dyax Corp. and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011